Download PDF
Seminars in Neurosurgery 2003; 14(3): 287-294
DOI: 10.1055/s-2004-828933
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Chemotherapy and Biological Therapy for Meningiomas

Stephen J. Hentschel, Ian E. McCutcheon
  • Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Further Information

Publication History

Publication Date:
02 June 2004 (online)

    Permissions and Reprints

ABSTRACT

The vast majority of meningiomas are benign neoplasms potentially curable with complete surgical resection. Radiotherapy is typically the adjuvant therapy of choice, once surgical options have been depleted, for recurrent or residual meningiomas requiring further therapy. Unfortunately, some meningiomas, not only atypical and malignant tumors but also benign tumors, recur despite maximal therapy with surgery and radiation. Thus, another effective form of adjuvant therapy is required in a small proportion of meningiomas. The most common chemotherapeutic agents in clinical practice are hormonal antagonists, targeting receptors known to be expressed by meningiomas, such as mifepristone, tamoxifen, medroxyprogesterone acetate (MPA), and pegvisomant. More recent evidence has suggested that hydroxyurea and interferon-α may be more effective therapy than hormonal antagonists for benign meningiomas. In contrast, malignant meningiomas are treated more like sarcomas with standard chemotherapeutic agents such as ifosfamide, doxorubicin, cisplatin, and dacarbazine. This article reviews the chemo- and biotherapeutic options available in the adjuvant therapy of meningiomas.

KEYWORDS

Meningioma - chemotherapy - adjuvant therapy

REFERENCES

  • 1 Rachlin J R, Rosenblum M L. Etiology and biology of meningiomas. In: Al-Mefty O, ed. Meningiomas New York: Raven Press 1991: 22-37
    Google Scholar
  • 2 Mirimanoff R O, Dosoretz D E, Linggood R M, Ojemann R G, Martuza R L. Meningioma: analysis of recurrence and progression following neurosurgical resection.  J Neurosurgery . 1985;  62 18-24
    CrossrefPubMedGoogle Scholar
  • 3 Simpson D. Recurrence of intracranial meningiomas after surgical treatment.  J Neurol Neurosurg Psychiatry . 1957;  20 22-39
    CrossrefPubMedGoogle Scholar
  • 4 Schoenberg B S, Christine B W, Whisnant J P. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer.  Neurology . 1975;  25 705-712
    PubMedGoogle Scholar
  • 5 Bickerstaff E R, Small J M, Guest I A. The relapsing course of certain meningiomas in relation to pregnancy and menstruation.  J Neurol Neurosurg Psychiatry . 1958;  21 89-91
    CrossrefPubMedGoogle Scholar
  • 6 Michelson J J, New P FJ. Brain tumor and pregnancy.  J Neurol Neurosurg Psychiatry . 1969;  32 305-307
    PubMedGoogle Scholar
  • 7 Courriere P, Tremoulet M, Eche N, Armand J P. Hormonal steroid receptors in intracranial tumours and their relevance in hormone therapy.  Eur J Cancer Clin Oncol . 1985;  21 711-714
    CrossrefPubMedGoogle Scholar
  • 8 Ironside J W, Battersby R D, Dangerfield V J, Parsons M A, Timperley W R, Underwood J C. Cryostat section assay of oestrogen and progesterone receptors in meningiomas: a clinicopathological study.  J Clin Pathol . 1986;  39 44-50
    PubMedGoogle Scholar
  • 9 Lesch K P, Schott W, Engl H G, Gross S, Thierauf P. Gonadal steroid receptors in meningiomas.  J Neurol . 1987;  234 328-333
    PubMedGoogle Scholar
  • 10 Markwalder T M, Zava D T, Goldhirsch A, Markwalder R V. Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features.  Surg Neurol . 1983;  20 42-47
    PubMedGoogle Scholar
  • 11 Schnegg J F, Gomez F, LeMarchand-Beraud T, de Tribolet N. Presence of sex steroid hormone receptors in meningioma tissue.  Surg Neurol . 1981;  15 415-418
    PubMedGoogle Scholar
  • 12 Kennedy B J, Yarbro J W. Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia.  JAMA . 1966;  195 1038-1043
    CrossrefPubMedGoogle Scholar
  • 13 Elford H L. Effect of hydroxyurea on ribonucleotide reductase.  Biochem Biophys Res Commun . 1968;  33 129-135
    CrossrefPubMedGoogle Scholar
  • 14 Krakoff I H, Brown N C, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea.  Cancer Res . 1968;  28 1559-1565
    PubMedGoogle Scholar
  • 15 Young C W, Schochetman G, Hodas S, Balis M E. Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships.  Cancer Res . 1967;  27 535-540
    PubMedGoogle Scholar
  • 16 Yarbro J W, Kennedy B J, Barnum C P. Hydroxyurea inhibition of DNA synthesis in ascites tumor.  Proc Natl Acad Sci U S A . 1965;  53 1033-1035
    PubMedGoogle Scholar
  • 17 Anand S, Verma H, Kumar L, Singh N. Induction of apoptosis in chronic myelogenous leukemia lymphocytes by hydroxyurea and Adriamycin.  Cancer Lett . 1995;  88 101-105
    CrossrefPubMedGoogle Scholar
  • 18 Schrell U M, Rittig M G, Anders M. et al . Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.  J Neurosurg . 1997;  86 845-852
    CrossrefPubMedGoogle Scholar
  • 19 Schrell U M, Rittig M G, Kiesewetter F, Adams E, Anders M. Hydroxyurea is a powerful inhibitor of meningioma cell growth. Evidence that hydroxyurea induces apoptosis in cultured meningioma cells and nude mice meningioma transplants [abstract].  Zentralbl Neurochir . 1996;  suppl 57 38-39
    PubMedGoogle Scholar
  • 20 Schrell U M, Rittig M G, Koch U, Marschalek R, Anders M. Hydroxyurea for treatment of unresectable meningiomas.  Lancet . 1996;  348 888-889
    PubMedGoogle Scholar
  • 21 Schrell U M, Rittig M G, Anders M. et al . Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.  J Neurosurg . 1997;  86 840-844
    CrossrefPubMedGoogle Scholar
  • 22 Mason W P, Gentili F, Macdonald D R, Hariharan S, Cruz C R, Abrey L E. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.  J Neurosurg . 2002;  97 341-346
    CrossrefPubMedGoogle Scholar
  • 23 Newton H B, Slivka M A, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma.  J Neurooncol . 2000;  49 165-170
    CrossrefPubMedGoogle Scholar
  • 24 Rosenthal M A, Ashley D L, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea.  J Clin Neurosci . 2002;  9 156-158
    CrossrefPubMedGoogle Scholar
  • 25 Giordano F, Savarino A, Pagni C A. Spinal meningioma during hydroxyurea therapy. A paradoxical case report.  Neurol Sci . 2002;  23 127-129
    CrossrefPubMedGoogle Scholar
  • 26 Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang Z J, Langstrom B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography.  Clin Cancer Res . 2001;  7 2269-2276
    PubMedGoogle Scholar
  • 27 Dinney C P, Bielenberg D R, Perrotte P. et al . Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration.  Cancer Res . 1998;  58 808-814
    PubMedGoogle Scholar
  • 28 Sidky Y A, Borden E C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.  Cancer Res . 1987;  47 5155-5161
    PubMedGoogle Scholar
  • 29 Baron S, Tyring S K, Fleischmann Jr R W. et al . The interferons. Mechanisms of action and clinical applications.  JAMA . 1991;  266 1375-1383
    CrossrefPubMedGoogle Scholar
  • 30 Golomb H M, Jacobs A, Fefer A. et al . Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.  J Clin Oncol . 1986;  4 900-905
    PubMedGoogle Scholar
  • 31 Niederle N, Moritz T, Kloke O. et al . Interferon alfa-2b in acute- and chronic-phase chronic myelogenous leukaemia: initial response and long-term results in 54 patients.  Eur J Cancer . 1991;  27 (suppl 4) S7-S14
    PubMedGoogle Scholar
  • 32 Ricketts R R, Hatley R M, Corden B J, Sabio H, Howell C G. Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood.  Ann Surg . 1994;  219 605-612
    CrossrefPubMedGoogle Scholar
  • 33 Neidhart J A. Interferon therapy for the treatment of renal cancer.  Cancer . 1986;  57 1696-1699
    PubMedGoogle Scholar
  • 34 Creagan E T, Ahmann D L, Frytak S, Long H J, Itri L M. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients.  Cancer . 1986;  58 2576-2578
    PubMedGoogle Scholar
  • 35 Jakacki R I, Cohen B H, Jamison C. et al . Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas.  J Neurosurg . 2000;  92 255-260
    CrossrefPubMedGoogle Scholar
  • 36 Koper J W, Zwarthoff E C, Hagemeijer A. et al . Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.  Eur J Cancer . 1991;  27 416-419
    PubMedGoogle Scholar
  • 37 Zhang Z J, Muhr C, Wang J L. Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells.  Anticancer Res . 1996;  16 717-723
    PubMedGoogle Scholar
  • 38 Kaba S E, DeMonte F, Bruner J M. et al . The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.  Neurosurgery . 1997;  40 271-275
    CrossrefPubMedGoogle Scholar
  • 39 Couzinet B, Le Strat N, Ulmann A, Baulieu E E, Schaison G. Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone).  N Engl J Med . 1986;  315 1565-1570
    PubMedGoogle Scholar
  • 40 Baulieu E E. The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications.  Endocrinol Metab Clin North Am . 1991;  20 873-891
    PubMedGoogle Scholar
  • 41 Baulieu E E. Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor.  Science . 1989;  245 1351-1357
    CrossrefPubMedGoogle Scholar
  • 42 Olson J J, Beck D W, Schlechte J, Loh P M. Hormonal manipulation of meningiomas in vitro.  J Neurosurg . 1986;  65 99-107
    PubMedGoogle Scholar
  • 43 Olson J J, Beck D W, Schlechte J A, Loh P M. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice.  J Neurosurg . 1987;  66 584-587
    PubMedGoogle Scholar
  • 44 Grunberg S M, Weiss M H, Spitz I M. et al . Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.  J Neurosurg . 1991;  74 861-866
    CrossrefPubMedGoogle Scholar
  • 45 Lamberts S W, Tanghe H L, Avezaat C J. et al . Mifepristone (RU 486) treatment of meningiomas.  J Neurol Neurosurg Psychiatry . 1992;  55 486-490
    PubMedGoogle Scholar
  • 46 Benson J R, Pitsinis V. Update on clinical role of tamoxifen.  Curr Opin Obstet Gynecol . 2003;  15 13-23
    CrossrefPubMedGoogle Scholar
  • 47 Clemons M, Danson S, Howell A. Tamoxifen (“Nolvadex”): a review.  Cancer Treat Rev . 2002;  28 165-180
    CrossrefPubMedGoogle Scholar
  • 48 Goodwin J W, Crowley J, Eyre H J, Stafford B, Jaeckle K A, Townsend J J. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.  J Neurooncol . 1993;  15 75-77
    CrossrefPubMedGoogle Scholar
  • 49 Markwalder T M, Seiler R W, Zava D T. Antiestrogenic therapy of meningiomas-a pilot study.  Surg Neurol . 1985;  24 245-249
    CrossrefPubMedGoogle Scholar
  • 50 Zava D T, Markwalder T M, Markwalder R V. Biological expression of steroid hormone receptors in primary meningioma cells in monolayer culture.  Clin Neuropharmacol . 1984;  7 382-388
    PubMedGoogle Scholar
  • 51 Markwalder T M, Waelti E, Konig M P. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on receptor status of meningioma cytosols.  Surg Neurol . 1987;  28 3-9
    PubMedGoogle Scholar
  • 52 Jaaskelainen J, Laasonen E, Karkkainen J, Haltia M, Troupp H. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases.  Acta Neurochir (Wien) . 1986;  80 35-41
    CrossrefPubMedGoogle Scholar
  • 53 Oura S, Sakurai T, Yoshimura G. et al . Regression of a presumed meningioma with the antiestrogen agent mepitiostane. Case report.  J Neurosurg . 2000;  93 132-135
    PubMedGoogle Scholar
  • 54 Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni Jr F J. Acromegaly and gastrointestinal cancer.  Cancer . 1991;  68 1673-1677
    PubMedGoogle Scholar
  • 55 Chan J M, Stampfer M J, Giovannucci E. et al . Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.  Science . 1998;  279 563-566
    CrossrefPubMedGoogle Scholar
  • 56 Karey K P, Sirbasku D A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol.  Cancer Res . 1988;  48 4083-4092
    PubMedGoogle Scholar
  • 57 Friend K E, Radinsky R, McCutcheon I E. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist.  J Neurosurg . 1999;  91 93-99
    PubMedGoogle Scholar
  • 58 McCutcheon I E, Flyvbjerg A, Hill H. et al . Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.  J Neurosurg . 2001;  94 487-492
    PubMedGoogle Scholar
  • 59 Johnson M D, Woodard A, Okediji E J, Toms S A, Allen G S. Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.  J Neurooncol . 2002;  56 133-142
    CrossrefPubMedGoogle Scholar
  • 60 Rubins J B, Greatens T, Kratzke R A, Tan A T, Polunovsky V A, Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells.  Am J Respir Crit Care Med . 1998;  157 1616-1622
    PubMedGoogle Scholar
  • 61 Wejde J, Blegen H, Larsson O. Requirement for mevalonate in the control of proliferation of human breast cancer cells.  Anticancer Res . 1992;  12 317-324
    PubMedGoogle Scholar
  • 62 Sumi S, Beauchamp R D, Townsend Jr M C. et al . Inhibition of pancreatic adenocarcinoma cell growth by lovastatin.  Gastroenterology . 1992;  103 982-989
    PubMedGoogle Scholar
  • 63 Stewart D J, Dahrouge S, Wee M, Aitken S, Hugenholtz H. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas.  J Neurooncol . 1995;  24 189-194
    CrossrefPubMedGoogle Scholar
  • 64 Bernstein M, Villamil A, Davidson G, Erlichman C. Necrosis in a meningioma following systemic chemotherapy. Case report.  J Neurosurg . 1994;  81 284-287
    PubMedGoogle Scholar
  • 65 Kyritsis A P. Chemotherapy for meningiomas.  J Neurooncol . 1996;  29 269-272
    CrossrefPubMedGoogle Scholar
  • 66 Colvin O M. Antitumor alkylating agents. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology Philadelphia: Lippincott Williams & Wilkins; 2001: 363-375
    Google Scholar
  • 67 Stewart C F, Ratain M J. Topoisomerase interactive agents. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology Philadelphia: Lippincott Williams & Wilkins; 2001: 415-430
    Google Scholar
  • 67a Johnson S W, Stevenson J P, O'Dwyer P J. Cisplatin and its analogues. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology Philadelphia: Lippincott Williams & Wilkins; 2001: 376-387
    Google Scholar
  • 67b Rowinsky E W, Tolcher A W. Antimicrotubule agents. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology Philadelphia: Lippincott Williams & Wilkins; 2001: 431-451
    Google Scholar
  • 68 Stewart D J, Mikhael N Z, Nair R C. et al . Platinum concentrations in human autopsy tumor samples.  Am J Clin Oncol . 1988;  11 152-158
    PubMedGoogle Scholar
  • 69 Stewart D J. Pros and cons of intra-arterial chemotherapy.  Oncology . 1989;  3 20-26
    PubMedGoogle Scholar
  • 69a Chu E, Mota A C, Fogarasi M C. Antimetabolites. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology Philadelphia: Lippincott Williams & Wilkins; 2001: 388-414
    Google Scholar
  • 70 Chamberlain M C. Adjuvant combined modality therapy for malignant meningiomas.  J Neurosurg . 1996;  84 733-736
    PubMedGoogle Scholar
  • 71 Levin V A. Chemotherapy of primary brain tumors.  Neurol Clin . 1985;  3 855-866
    PubMedGoogle Scholar
  • 72 Wilson C B. Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider Lecture.  J Neurosurg . 1994;  81 666-675
    PubMedGoogle Scholar
  • 73 Coke C C, Corn B W, Werner-Wasik M, Xie Y, Curran Jr J W. Atypical and malignant meningiomas: an outcome report of seventeen cases.  J Neurooncol . 1998;  39 65-70
    CrossrefPubMedGoogle Scholar
  • 74 Zankl H, Zang K D. Correlations between clinical and cytogenetical data in 180 human meningiomas.  Cancer Genet Cytogenet . 1980;  1 351-356
    CrossrefPubMedGoogle Scholar
  • 75 Dirven C M, Grill J, Lamfers M L. et al . Gene therapy for meningioma: improved gene delivery with targeted adenoviruses.  J Neurosurg . 2002;  97 441-449
    PubMedGoogle Scholar
  • 76 Ikeda K, Saeki Y, Gonzalez-Agosti C, Ramesh V, Chiocca E A. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.  J Neurosurg . 1999;  91 85-92
    PubMedGoogle Scholar